Emsam (selegiline transdermal) / Viatris - LARVOL DELTA

Topical selegiline accelerates cutaneous wound healing with phase-specific modulation of MAPK signaling. (PubMed, Inflammopharmacology) - "Topical selegiline was associated with faster excisional wound repair, most consistently at 1-2%, by accelerating closure and coordinating inflammatory resolution, growth-factor recovery, apoptosis balance, and MAPK-related signaling across healing phases. These findings support further preclinical evaluation of topical selegiline, including mechanistic validation, local and systemic safety assessment, pharmacokinetic characterization, and investigation in impaired or chronic wound models."

Journal • Inflammation • Oncology • IL1B • IL6 • MAPK8 • TGFB1 • TNFA

A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (clinicaltrials.gov) - P1 | N=232 | Active, not recruiting | Sponsor: Corium Innovations, Inc. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects (clinicaltrials.gov) - P1 | N=92 | Completed | Sponsor: Corium Innovations, Inc. | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects (clinicaltrials.gov) - P1 | N=92 | Active, not recruiting | Sponsor: Corium Innovations, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Corium Innovations, Inc.

New P1 trial

Microneedle assisted drug delivery of liposome loaded with selegiline hydrochloride for effective management of Parkinson's disease intervention. (PubMed, J Liposome Res) - "A histopathological study showed improved neuronal regeneration for the SH-LP3-MNP formulation. Through these findings, it was reported that the SH-LP3-MNP formulation is a promising approach for delivering liposomes loaded with selegiline through the skin for the treatment of Parkinson's disease symptoms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Validation of the Brief Children's Depression Rating Scale in Children Treated With Selegiline Transdermal Patch vs Placebo. (PubMed, JAACAP Open) - P4 | "While citing references scientifically relevant for this work, we also actively worked to promote sex and gender balance in our reference list. While citing references scientifically relevant for this work, we also actively worked to promote inclusion of historically underrepresented racial and/or ethnic groups in science in our reference list."

Clinical • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (clinicaltrials.gov) - P1 | N=230 | Not yet recruiting | Sponsor: Corium Innovations, Inc.

New P1 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Corium Innovations, Inc. | Recruiting ➔ Completed

Trial completion

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. (PubMed, Pharmaceuticals (Basel)) - " Findings suggest that bromocriptine, amantadine, and selegiline may represent effective dopaminergic antidepressants, particularly for treatment-resistant or atypical depression. Further large-scale, methodologically rigorous studies are needed to confirm their clinical utility."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

EMSAM: enhanced multi-scale segment anything model for leaf disease segmentation. (PubMed, Front Plant Sci) - "Particularly, for images with moderate and severe disease levels, EMSAM achieved Dice Coefficients of 0.8354 and 0.8178, respectively, significantly outperforming other semantic segmentation algorithms. Additionally, the model achieved a classification accuracy of 87.86% across the entire dataset, highlighting EMSAM's effectiveness and superiority in plant disease segmentation and classification tasks."

Journal

Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects (clinicaltrials.gov) - P=N/A | N=12 | Recruiting | Sponsor: Corium Innovations, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2024 ➔ Feb 2025 | Trial primary completion date: Dec 2024 ➔ Mar 2025

Enrollment open • Trial initiation date • Trial primary completion date

Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression. (PubMed, J Affect Disord) - "Although oral MAOI therapy has been eschewed by most clinicians, STS may be better tolerated than oral MAOIs and TCAs."

Adverse events • Journal • Cardiovascular • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Formulation, development and in vivo characterization of selegiline hydrochloride nanostructured lipid nanocarrier loaded microneedle array patch for depression. (PubMed, Int J Pharm) - "Histopathology analysis revealed no significant toxicity to vital organs. Thus, a selegiline nanostructured lipid carrier-loaded microneedle array patch can increase brain bioavailability compared to a pure selegiline-loaded microneedle array patch for managing depression."

Journal • Preclinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects (clinicaltrials.gov) - P=N/A | N=12 | Not yet recruiting | Sponsor: Corium Innovations, Inc.

New trial

Drugs for depressionr. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Concomitant use of monoamine oxidase inhibitor and tyrosine in parenteral nutrition. (PubMed, Eur J Clin Nutr) - "We describe our experience with a 67-year-old woman with severe depression who was on the MAOI, transdermal selegiline...However, further study is needed to verify our findings beyond this one patient. In conclusion, we recommend initiating PN and increasing it to goal in patients taking MAOIs, gradually, while monitoring for hypertensive crisis given the theoretical possibility of the tyramine pressor response."

Journal • CNS Disorders • Depression • Psychiatry

The novel design of an intelligent anti-depression transdermal drug delivery system. (PubMed, Biomaterials) - "(3) A rat model of depression was established using chronic unpredictable mild stress (CUMS) combined with separation. From the aspects of behavior (body weight, sucrose preference test, forced swimming test, open field test) and biochemical indexes (serum proinflammatory cytokines (IL-1β, TNF-α), hippocampus HE staining observation), the therapeutic effect of hyperthermia, Selegiline oral administration and transdermal administration was discussed."

Journal • Anorexia • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • IL1B • TNFA

Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. (PubMed, Eur Neuropsychopharmacol) - "Selegiline did not differ from methylphenidate and ADHD scores (k = 2). Confidence in findings was low/very-low for most outcomes; moderate for depressive symptoms reduction (transdermal). Selegiline proved effective, safe, and well-tolerated for depressive disorders, yet further evidence is warranted about specific psychiatric disorders."

Journal • Retrospective data • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Dental Disorders • Depression • Insomnia • Major Depressive Disorder • Mental Retardation • Mood Disorders • Pain • Psychiatry • Schizophrenia • Sleep Disorder • Xerostomia

Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials (MDS Congress 2022) - "Twelve drugs available in Japan for PD patients with wearing-off (pramipexole IR/ER, ropinirole IR/ER/transdermal patch, rotigotine transdermal patch, entacapone, opicapone, istradefylline, selegiline, rasagiline, and safinamide) were included in the study...For Off-time, 11 out of 12 active drugs were superior to placebo, and SUCRA was greater for ropinirole transdermal patch (86.1%), pramipexole IR (76.2%), ropinirole ER (75.0%), and safinamide (69.1%)... We found balanced efficacy and tolerability in dopamine agonists and safinamide. Further studies will be needed since the number of head to head trials was limited."

Retrospective data • CNS Disorders • Parkinson's Disease

The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles. (PubMed, Psychopharmacol Bull) - "This review article features comprehensive discussions on the dietary restrictions issued to patients taking a classic monoamine oxidase inhibitor (phenelzine, tranylcypromine, isocarboxazid), or high-dose (oral or transdermal) selegiline. Minimizing the intake of the small number of risky foods is all that is required. Many patients may hardly need to change their diet at all."

Journal • Review

MAOIs for Trainees (APA 2022) - "Data from 2018-2019 indicated that off all Antidepressants, only 0.035% of those prescribed were MAOIs (with 0.015% being Parnate and 0.010% being EMSAM). Currently, many popular texts and teaching do not incorporate the knowledge base that has developed since the advent of MAOIs (particularly around original fears related to drug-drug interactions, diet, and blood pressure). This poster will summarize the current thinking on MAOIs and will present a pilot program to teach residents how to safely & effectively use these medications."

Combinations of pharmacological treatments in smoking cessation. A systematic review (PubMed, Rev Mal Respir) - "Combination treatments can achieve higher smoking abstinence rates than monotherapies, especially in smokers who have failed to quit (Hard-core smokers). Treatment with a combination of varenicline and nicotine replacement therapy is a therapeutic option in smoking cessation."

Journal • Review • Nicotine Addiction • Tobacco Addiction • Tobacco Cessation

Transdermal route: A viable option for systemic delivery of antidepressants. (PubMed, J Pharm Sci) - "A number of conventional and emerging transdermal delivery strategies have been investigated for some potent antidepressants and results depict the potential of this route as a viable means for systemic delivery of therapeutically relevant doses of the tested agents, with Emsam®, the commercially available patch of selegiline, being an evidence for the same. The investigated approaches include the formulation of transdermal patches, use of vesicular drug carriers, pro-drug approach, microemulsification, chemical as well as physical enhancement technologies. This review provides a comprehensive account of the rationale, developments made till date, scope and future prospects of delivering antidepressants via the transdermal route of administration."

Journal • Review • CNS Disorders • Depression • Psychiatry

[VIRTUAL] Evaluation of Combination Treatment With Monoamine Oxidase Inhibitors and Stimulants (APA 2021) - "Clinical Case: The patient is a 31 yo man with TRD and attention deficit-hyperactivity disorder (ADHD) who had failed numerous trials comprising multiple antidepressant classes (including ketamine) and somatic therapies (electroconvulsive therapy [ECT] and transcranial magnetic stimulation [TMS])...Here we report the patient’s treatment course on transdermal selegiline in combination with mixed amphetamine salts (on which he had been maintained for some time)... A Medline/Pubmed search yielded 3638 articles including duplicated, which were screened by title to obtain 63 associated articles including duplicates. Duplicates were removed 42 articles were further screened by title and abstract which resulted in 25 articles. The 25 full-text articles were further reviewed and met full criteria and were included in this review."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Epilepsy • Immunology • Psychiatry • Suicidal Ideation